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Abstract
Background: Many recent Stroke trials fail to show a beneficial effect of the intervention late in the development.
Currently a large number of new treatment options are being developed. Multi-arm multi-stage (MAMS) designs
offer one potential strategy to avoid lengthy studies of treatments without beneficial effects while at the same time
allowing evaluation of several novel treatments.
In this paper we provide a review of what MAMS designs are and argue that they are of particular value for Stroke
trials. We illustrate this benefit through a case study based on previous published trials of endovascular treatment
for acute ischemic stroke.
We show in this case study that MAMS trials provide additional power for the same sample size compared to
alternative trial designs. This level of additional power depends on the recruitment length of the trial, with most
efficiency gained when recruitment is relatively slow. We conclude with a discussion of additional considerations
required when starting a MAMS trial.
Conclusion: MAMS trial designs are potentially very useful for stroke trials due to their improved statistical power
compared to the traditional approach.
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Background
It is well recognised that drug development is costly and
time consuming [1] yet in recent years about half of
Phase III trials and 80% of Phase II studies undertaken
have been unsuccessful [2, 3]. While it is undesirable for
every trial to conclude superiority of the experimental
treatment – this would raise the question why such
studies are done at all – it is widely agreed that these
figures are unacceptably high. The situation in stroke is
no better with several recent studies failing to show
superiority of the experimental treatment [4–6]. In
addition to the cost, many patients have been exposed to
ineffective, possibly even harmful, treatments.
There are 19 distinct treatments for stroke currently
under development [7] – about half undergoing Phase II
studies. Accounting for different doses of the same
treatment and combinations of treatments, the number
of potential experimental treatment arms in stroke to be
evaluated in trials in the next few years is huge. Evaluat-
ing all in traditional randomized controlled Phase III
studies will lead to competition to recruit patients to
each of the studies. A large number of patients will be
allocated to control treatments, as each trial requires a
separate control group. Moreover if past trends con-
tinue, many patients will be exposed to treatments that
will ultimately be found to be ineffective. To address
these issues, alternative designs need to be considered.
In this work we will discuss the potential utility of
combining multiple experimental arms into a single
multi-arm trial for improving evaluating treatments in
stroke. We also consider going further and considering
an adaptive approach called a multi-arm multi-stage
(MAMS) design, which allows elimination of ineffective
treatments while reducing the number of patients
allocated to a control treatment.
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We first consider these designs and their advantages
in more detail. We then argue why they are particularly
suitable for stroke trials. Next, we consider a case study
that illustrates the potential advantages using an ex-
ample of two randomised trials in endovascular treat-
ment for acute ischemic stroke. We end the paper with




A multi-arm trial compares several different experimen-
tal treatments against a common control group within a
single study. An immediate desirable consequence of
this set-up is that only a single control group is required,
reducing the number of patients on the control treat-
ment compared to separate two-arm evaluations. The
reduction in sample size for a trial with 3 experimental
arms versus conducting 3 separate two-arm trials is
around 15%. Additionally patients are more likely to be
randomized to an experimental treatment – a feature
that helps recruiting patients [8, 9]. Multi-arm designs
also offer the unique opportunity for a fair head-to-head
comparison of experimental treatments within the same
study. This is due to the same patient population being
studied, all patients following the same protocol and use
of the same comparator group.
Multi-arm multi-stage trials
Similarly to group-sequential designs for two arm
studies [10], efficiency can be gained by the inclusion of
interim analyses. At each interim analysis, test statistics
based on all patients assessed up to that point are calcu-
lated to compare the effect of each (remaining) experi-
mental treatment to control. These test statistics are
used to select which treatment(s) should be continued
and which should be stopped. An arm is stopped
either because the evidence so far suggests that the
treatment is unlikely to be superior to control (known
as lack-of-benefit, or futility stopping) or because the
accumulated evidence is already sufficient to claim
superiority of that treatment arm (known as efficacy
stopping). For the control arm and every remaining
experimental arm, further patients are recruited until
a decision has been reached or until a maximum
number of analyses is reached.
Figure 1 illustrates such a multi-arm multi-stage
(MAMS) design. In this example four experimental
treatments and three analysis time points are used. At
the first interim analysis, the test statistics for treatment
1 and 4 are below a pre-specified lower bound implying
that they are unlikely to be superior to control. As a
consequence no further patients are randomized to these
treatments. Neither of the test statistics for treatment 2
and 3 exceeds the upper bound of the design at the first
analysis so further patients are randomized to those
treatments and control. At the second analysis, the test
statistic for treatment 2 exceeds the upper boundary so
that superiority for this treatment over control can be
concluded. In this example no further patients are
randomized as a successful treatment has already been
found. Alternatively, one could continue with the last
remaining treatment and control until a definitive
decision for this treatment has also been reached.
Different ideas have been proposed for how to select
which experimental treatments should continue at the
interim analyses. The example above selects all treat-
ments that are deemed sufficiently promising [11, 12]
while alternatively only the best or the best few could
also be chosen [12]. Common to all these designs is that
by allowing for treatment selection the number of pa-
tients recruited in the trial is typically markedly smaller
than without treatment selection at an interim analysis.
Practical considerations when conducting multi-arm
multi-stage designs
As argued above, a multi-arm design will be more
efficient than separate two-arm studies. However, a few
points need to be noted. Firstly, despite the sample size
often being smaller than for a study without interim
analysis, there is a small chance that the sample size is
increased as well. This is due to the need to account for
possible wrong decisions at the interim analyses. Sec-
ondly, (notable) reductions in patient numbers are only
possible if the endpoint utilized for treatment selection
(typically the primary endpoint or some short-term sur-
rogate) is observed quickly relative to the recruitment
rate. The reason for this is that, in an extreme scenario,
all patients could already be recruited by the time the in-
formation from assessed patients is available for making
the treatment selection decision. Thirdly, since all of the
experimental treatments start at an equal footing, none
of them should have strong evidence of superiority to
the others at the onset of the study. In the case where
there is a treatment that is highly likely to be the best
treatment, the most efficient approach would be to just
test that treatment against control. Finally, the
organization of interim analyses must be efficient, with
data monitoring and statistical analysis done to tight
deadlines [13]. Additional resources are required to con-
duct and additional effort to maintain blinding. However,
these issues are also present in traditional RCTs as data
monitoring committees are regularly provided with
unblinded trial data.
In addition to the general considerations above – most
of which are also relevant for traditional two-armed
studies with interim analyses, some additional adminis-
trative and operational aspects need to be considered
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which mean that the time to set up a MAMS study is
typically longer than for a traditional study, although
substantially less than the time to set up multiple separ-
ate trials. Firstly, different trials often are initiated by dif-
ferent centres, have different inclusion and exclusion
criteria, and may use different primary and secondary
endpoints. All of these must be standardised for a
multi-arm trial which may require negotiations and
compromises between investigators.
Secondly, it is more difficult to explain MAMS trials
to patients. Providing informed consent requires that pa-
tients are aware of all the possibilities. The STAMPEDE
trial, for example, addressed this through use of a
two-part patient information sheet [14]: summary infor-
mation on all arms is provided before randomisation; de-
tailed information of the allocated therapy is provided
after randomisation. The more detailed information can
be requested on all arms prior to randomisation.
Planning and ensuring treatment supply poses the
third challenge. Due to the fact that arms can be
stopped, the maximum drug supply for each arm is un-
certain. While the same can be said for group-sequential
designs this issue is more pronounced in MAMS studies
due to the use of multiple arms. This issue is further
exaggerated when multiple centres and countries are
taking part in the study. Consequently the use of
advanced prediction approaches for multi-centre trials is
paramount [15].
A fourth challenge is to ensure that no bias in the
evaluation is introduced by an imbalance in the alloca-
tion of treatments across centres and regions. It is
therefore important to stratify randomization by centre
or region. Doing so also simplifies prediction of the drug
supply to the different centres as within centre imbal-
ances are reduced.
It is our belief that more complex administration and
operation is vastly outweighed by the improved effi-
ciency and reduced exposure of patients to potentially
harmful treatments. These administration and operation
hurdles have successfully been overcome in a variety of
other therapeutic areas [16–20]. Even within Stroke, the
ASTIN study has been undertaken [21]. Thus, we be-
lieve that some of the objections often raised are based
on misconceptions. For example, concerns about a much
more elaborate ethical approval process rarely hold true.
As a MAMS design is a single study under a single
Fig. 1 Illustration of a multi-arm multi-stage design. Crosses represent the test statistic at each analysis for each of the experimental arms against
control. The upper dashed line represents the efficacy boundary (with a treatment being recommended as superior to control if the test statistic
is above this), and the lower dash-dotted line represents the futility boundary (with the treatment being stopped early for lack of benefit if the
test statistic is below this)
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protocol, the only difference in obtaining approval is that
now several treatments need to be deemed worthy of
experimentation. Concerns about public funders being
unwilling to fund such designs have also been proven
false in other areas [17, 22, 23].
Why MAMS trials are suitable for stroke
So far our description of MAMS designs has been gen-
eric and made little reference to the specifics of stroke
trials. It is our belief that trials in stroke are particularly
suited for MAMS. The reasons include:
1. Numerous treatments/regimens are currently in the
early development stages and hence soon available
for large scale testing [7].
2. Trials in stroke tend to be large resource intensive
studies. Eliminating ineffective treatments prevent
delays in evaluating alternative treatments.
Additionally the savings in resources from dropping
an ineffective arm are large.
3. The primary outcome measure, often the modified
Rankin scale [24] or the Barthel index [25], are
usually measured 90 days after treatment initiation
and hence quickly observed.
4. Current failure rates are high so it can be expected
that many treatments can be eliminated from the
study quickly.
5. Information about the relative merits of different
treatment options is limited due to success in early
studies being a poor predictors of success in late
stage trials [26].
In the next section we will illustrate, based on real
studies, the potential utility of multi-arm multi-stage
designs in stroke.
Case study
We consider two completed randomised controlled trials
of endovascular treatment for acute ischemic stroke with
similar inclusion criteria (Ciccone et al. [5], Broderick et
al. [6]) that both used intravenous t-PA therapy as the
control. Ciccone et al. [5] used endovascular therapy
alone as the experimental treatment while intravenous
t-PA with endovascular therapy was used in Broderick et
al. [6] Both trials used a dichotomisation of the modified
Rankin scale at 3 months as the primary outcome. A
score of 0 or 1 was defined as a success in Ciccone et al.
while a score of 0–2 was classed as a success in Broderick
et al. Neither trial found a significant difference between
the experimental therapy and the control arm. Table 1
shows the percentage of patients for each of the modified
Rankin categories in each treatment arm. Irrespective of
the definition of success used, both experimental arms
were slightly worse than intravenous t-PA.
Subsequently we will compare several design possibil-
ities in terms of the power and sample size required.
These are: 1) two separate trials, each testing one of the
experimental treatments against control; 2) a three-arm
MAMS design; 3) two separate group-sequential trials,
each testing one of the experimental treatments against
control; 4) a multi-arm trial but no possibility of early
stopping. In reality, the sample size used in each trial
was not the same, so we simplify comparisons by consid-
ering equal numbers of patients recruited per arm in the
multi-arm and MAMS trial, and equal numbers of pa-
tients in the separate trial and separate group-sequential
trials setting. The total number of patients assessed in
the two trials was 991. To allow fair comparisons, we set
the number of patients per arm in each case so that the
maximum sample size was close to this value. The two
Table 1 Proportion of patients in each category of the modified




t-PA (n = 395)
Endovascular




0 11.9% 12.2% 12.8%
1 18.7% 18.2% 16.6%
2 12.4% 11.5% 13.3%
3 15.9% 20.4% 17.1%
4 17.2% 17.7% 15.4%
5 7.1% 5.5% 4.8%
6 16.7% 14.3% 20.0%
Odds ratio (success = 0 or 1) 0.991 0.944
Odds ratio (success = 0–2) 0.956 0.988
Table 2 Properties of MAMS design and running two separate trials
Design Treatments ineffective One treatment effective
Total type-I error rate Expected sample size Power to recommend effective treatment Expected sample size
MAMS, futility only, two-stage 0.033 623 0.761 834
Separate trials 0.034 992 0.644 992
Separate trials, group-sequential 0.036 608 0.625 764
Multi-arm, no interim analyses 0.036 990 0.782 990
As described further in the manuscript, the ‘Treatments ineffective’ scenario uses a success probability of 0.304 for the control treatment, 0.302 for the first
experimental treatment and 0.294 for the last arm. The ‘one treatment effective’ scenario uses 0.404 for one experimental treatment while the other two arms use
0.304. Statistical properties are found by approximating the log-odds ratio as normally distributed
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separate trials each have a sample size of 248 per arm
(992 in total), the MAMS trial has 165 patients per arm
per stage (a maximum of 990), the two separate
group-sequential designs each have 124 patients per arm
per stage (maximum 992) in total, and the multi-arm
trial recruits 330 patients per arm (total 990).
For both the MAMS and separate group-sequential
trials, we include a single interim analysis that eliminates
treatments for futility. Triangular stopping boundaries
[27] (Fig. 1) are used, due to its good properties [28].
For the MAMS trial, the futility test statistic thresh-
old is 0.662 and the final critical value is 1.866. In
terms of p-values, this is equivalent to a futility
threshold of 0.254 (i.e. if the p-value for a comparison
is above 0.254 at the interim the corresponding
experimental arm is dropped) and a final critical
value of 0.031 (i.e. superiority can be concluded if the
final p-value is below 0.031). Each separate group-se-
quential trial has a futility test statistic threshold of
0.678 and a final critical value of 1.917 (in terms of
p-values, 0.249 and 0.028 respectively). These values
and the critical values used in the other two designs
were chosen to limit the maximum chance of making
a type I error to 5%.
We consider two scenarios: 1) the three treatments
(two experimental and control) have the same treatment
effect as found in the real trials (Table 1, with success
defined as a 0 or 1); 2) a hypothetical scenario where
intraveneous t-PA and endovascular therapy alone both
have the success probabilities of 0.306, and intraveneous
t-PA combined with endovascualar therapy has a success
probability of 0.406. The statistical characteristics of the
MAMS designs and the two separate trials are calculated
by using a normal approximation for the log-odds ratio
and applying methods from Magirr et al. [11] These
results are summarised in Table 2. For the first scenario,
the probability of recommending a truly ineffective
treatment and the expected sample size is given. For the
second scenario, the probability of recommending the
truly effective treatment and the expected sample size is
given.
Table 2 shows that the MAMS design has a high
power and a low expected sample size. It has a consider-
ably lower expected sample size than separate trials and
the multi-arm trial, but has a considerably higher power
than separate trials and separate group-sequential trials.
This indicates the MAMS design is likely to drop inef-
fective treatments. The type I error rate for all ap-
proaches is similar. Figure 2 shows the expected sample
size and power of all four designs as the effectiveness of
the second experimental arm varies. The power of the
MAMS trial is close to the multi-arm trial (which has
the highest power) while the expected sample size is
close to that of the separate group-sequential trials
design, especially when the treatment effect is low.
Although separate group-sequential trials have a lower
expected sample size than the MAMS study, this reduc-
tion comes at the cost of substantially reduced power
(which corresponds to a 37% drop in sample size).
The results in Table 2 and Fig. 2 ignore the fact
that there is delay between recruiting an individual
and assessing the modified Rankin score. This delay
Fig. 2 Plots of a) power and b) expected sample size of separate
trials and MAMS trial as the probability of success of one experimental
arm changes. Probability of success for the other arms is 0.309. MAMS:
multi-arm multi-stage; GS: group-sequential
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causes a loss of efficiency in trial designs that use in-
terim analyses which depends on the length of the
delay and the recruitment rate. Hence using a quickly
observed outcome will ensure that this loss is kept
small. Figure 3 shows the expected sample size of the
MAMS design, for a 90-day delay, as the recruitment
rate of the trial increases. The efficiency, in terms of
expected sample size, of the MAMS design goes
down as the recruitment rate increases. The recruit-
ment of the two previous two trials [5, 6] combined
is around 17.5 patients per month. For this rate, there
is still a substantial advantage to using a MAMS
design, primarily because of the short assessment
delay in stroke trials. We do not recommend pur-
posely slowing recruitment, as this would increase the
trial costs in different ways. Instead we recommend
considering the likely recruitment rate and whether




In this manuscript we illustrate, based on real trial
examples, that multi-arm multi-stage (MAMS) designs
allow efficient evaluation of multiple treatments as
ineffective treatments are quickly eliminated while the
number of patients on control is kept small. Although
our evaluation is focussed on evaluating 2 experimental
arms simultaneously, gains in efficiency are even larger
as the number of experimental arms increases. Another
point to note here is that the different arms could also
be different doses of the same treatment or combina-
tions of treatments.
Limitations of MAMS
There are clear efficiency reasons to use a MAMS
design, yet there are a number of practical challenges
that need to be considered when embarking on their
use. In order to be able to utilize these different arms in
Fig. 3 Expected sample size of MAMS design as monthly recruitment rate changes. Constant recruitment is assumed and a 90 day delay is
assumed between recruitment and observing the primary endpoint. Vertical dotted line represents recruitment rate of trials described in Ciccone
et al. and Broderick et al. combined
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a MAMS design, treatments must be available for testing
at the same time making it crucial to coordinate spon-
sors, investigators and ethical and regulatory approvals.
Additionally the consent procedures and information to
patients are more complex than for standard two-arm
studies as they need to account for all potential treat-
ments in the study.
An interesting question arising in MAMS trials is
whether or not it is important to control the total
chance of making a type I error. In the case of running
separate trials, it would not normally be required to ad-
just the significance level used in one trial because of the
existence of another trial in the same condition. How-
ever arguably it is important to control a trial’s chance
of recommending an ineffective treatment, which would
imply it is necessary to control the chance of making
any type I error. Some other papers [29, 30] have consid-
ered this debate in more detail, and we refer the inter-
ested reader to them.
Other types of MAMS designs have also been
proposed, including using adaptive randomisation [31]
and drop-the-losers [32]. Arguably it is a limitation that
there is an array of design options available as it makes
it confusing which one should be used in practice.
Clearly careful consideration at the design stage of a
MAMS trial is required.
Conclusion
Despite the practical and statistical challenges, we
believe that the benefits derived from MAMS designs
clearly outweigh running multiple two-arm studies, so
that they should be considered regularly for stroke trials.
As these designs become more regularly used the
expertise gained in setting up such studies will help to
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